

Cover Story
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
In Brief


Drugs & Targets
Trending Stories
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Biden’s FY23 proposal cuts NCI funds by $199M, while boosting ARPA-H by $4B
- Trump et al. focus on NIH, cancer—and how peer review is done
- Fired NCI employee says Trump’s purge was baseless yet punitive
“I feel like I’ve been erased” - Bhattacharya provides calm answers to anxious questions at confirmation hearing
Trump nominee for NIH director calls for transparency, audits of indirect costs - In The Headlines: When DOGE fires you from your dream job